Oncolytic virus (OV)

Oncolytic virotherapy can self-amplify intratumorally, thereby increasing its dose in situ. This innovative approach holds promise for cancers resistant to existing treatments.

Oncolytic viruses (OVs) have been shown to:

• Induce antitumor immune responses


• Augment the efficacy of existing cancer treatments


• Reform unresponsive TMEs to turn ‘cold’ tumors ‘hot,’ increasing their susceptibility to checkpoint blockade immunotherapies

For this reason, Oncolytic virus (OV) serve as ideal complements to Immune checkpoint inhibitors (ICIs). Multiple preclinical studies and clinical trials are demonstrating their combined therapeutic efficacy.
Hwang et al. 2020a

Oncolytic viruses were divided with respect to the genome in DNA and RNA viruses
Rius-R…